The GW VRU was a site for the phase 1, double-blind clinical trial to examine the safety and immunogenicity of a replication-competent recombinant vesicular stomatitis virus-vectored vaccine to reduce the risk of infection and severe illness from Lassa Fever. A total of 114 adults were enrolled, and no serious vaccine-related adverse events were reported. The vaccine had immunogenicity across the study population in the United States and Liberia.
Photo Credit: AMI IMAGES / SCIENCE PHOTO LIBRARY
